Skip to content
This GLP
← Research
Evidence

Intracranial pressure: the vision results look real, the death rate does not

A meta-analysis reports 80% fewer deaths in a condition that rarely kills. That figure calibrates everything else in the table.

Ruth Alvarez7 min read
Reported risk ratiosheadache0.73needing surgery0.76visual worsening0.51papilledema0.38death0.20← implausibleA condition that threatens sight, not life.

Idiopathic intracranial hypertension raises pressure inside the skull, causes severe headache and swells the optic nerve, and weight loss is one of the few things established to help it. A drug that produces large weight loss should therefore work, and a meta-analysis of nine studies covering 13,257 participants reports that it does [1]. The eye is somewhere these drugs have produced mixed signals before, as the optic nerve evidence by indication shows.

The clinical outcomes go the expected way. Headache risk came in at a risk ratio of 0.73 (95% CI 0.61–0.86), papilledema at 0.38 (95% CI 0.25–0.56), visual worsening at 0.51 (95% CI 0.37–0.68), and needing surgical intervention at 0.76 (95% CI 0.65–0.89). Mechanistically this is about as plausible as findings in this field get.

The reason to dwell on an implausible number rather than ignore it is that it calibrates the others. The mortality estimate and the papilledema estimate come from the same studies, comparing the same people. Whatever made the treated group so much less likely to die — being younger, healthier, better engaged with care, well enough to be offered an injection — was also making them less likely to lose vision. So the direction of the vision findings is probably right and the size of them is almost certainly inflated.

Nine studies, mostly observational, is what this evidence base consists of. The meta-analysis did exclude studies of patients with prior IIH treatment, which removes one source of confusion, but nothing randomized anyone to anything. The single randomized trial in this area is covered on this site’s sister publication rather than restated here.

For someone with this diagnosis the practical position is reasonable and the numbers are not. Weight loss helps intracranial pressure, these drugs produce weight loss, and a neuro-ophthalmologist weighing one is on defensible ground. Reading 0.38 as the papilledema benefit to expect is not defensible, for the same reason that a mortality hazard ratio the authors disowned and the dialysis cohort need their baseline tables read first — and the same reason the overdose comparison gave five different answers.

Frequently asked

Do these drugs help idiopathic intracranial hypertension?
Probably, in direction. Weight loss is established to lower intracranial pressure and the reported outcomes all point that way. The effect sizes are likely inflated by differences between treated and untreated groups.
Why single out the mortality result?
Because the condition threatens sight rather than life, so an 80% reduction in deaths cannot be a drug effect. It reveals how different the compared groups were, which affects every other estimate from the same studies.
Is there randomized evidence?
Very little. This meta-analysis pooled nine mostly observational studies, and nothing in it randomized patients to treatment.

Sources

  1. [1] Ahmed W, Gandhi OH, Yu N, Brant J, et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis Journal of the Neurological Sciences. PMID 41468715

Where to get it

Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

Compare providers →

More in Evidence